RenovoRx Inc
NASDAQ:RNXT

Watchlist Manager
RenovoRx Inc Logo
RenovoRx Inc
NASDAQ:RNXT
Watchlist
Price: 0.9401 USD -2.07% Market Closed
Market Cap: 34.5m USD

Relative Value

The Relative Value of one RNXT stock under the Base Case scenario is 3.3846 USD. Compared to the current market price of 0.9401 USD, RenovoRx Inc is Undervalued by 72%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RNXT Relative Value
Base Case
3.3846 USD
Undervaluation 72%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
27.7
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.8
Industry
23.7
Forward
-2.9
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.9
Industry
22
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.9
Industry
23.8
vs History
37
vs Industry
17
Median 3Y
4.4
Median 5Y
3.5
Industry
3.3
vs History
20
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
19.6
vs History
20
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
29
Median 3Y
-1.7
Median 5Y
-1.7
Industry
6.4
vs History
vs Industry
28
Median 3Y
-1.7
Median 5Y
-1.7
Industry
7
Forward
-2
vs History
vs Industry
29
Median 3Y
-1.9
Median 5Y
-1.9
Industry
8.3
vs History
vs Industry
26
Median 3Y
-1.9
Median 5Y
-1.9
Industry
6.5
vs History
25
vs Industry
0
Median 3Y
44.7
Median 5Y
43.6
Industry
5.7

Multiples Across Competitors

RNXT Competitors Multiples
RenovoRx Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
RenovoRx Inc
NASDAQ:RNXT
34.5m USD 37.1 -3.1 -2.1 -2.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
395.1B USD 6.6 168.3 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
174.1B USD 4.8 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 9.8 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD 5.5 17 16.1 18.3
AU
CSL Ltd
ASX:CSL
85.8B AUD 3.7 19 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.3 1 204.2 158.2 191.8
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.5 34 58.7 60.3
P/S Multiple
Revenue Growth P/S to Growth
US
RenovoRx Inc
NASDAQ:RNXT
Average P/S: 3 067 334.4
37.1
724%
0.1
FR
Pharnext SCA
OTC:PNEXF
33 738 486.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 088.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
P/E Multiple
Earnings Growth PEG
US
RenovoRx Inc
NASDAQ:RNXT
Average P/E: 189.6
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.3
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 204.2
N/A N/A
NL
argenx SE
XBRU:ARGX
34
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
RenovoRx Inc
NASDAQ:RNXT
Average EV/EBITDA: 39.4
Negative Multiple: -2.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.7
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
RenovoRx Inc
NASDAQ:RNXT
Average EV/EBIT: 45.5
Negative Multiple: -2.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.8
N/A N/A
NL
argenx SE
XBRU:ARGX
60.3
N/A N/A